Abstract:Objectives and design:Developing an effective HIV-1 vaccine that elicits broadly neutralizing HIV-1 human antibodies (bnAbs) remains a challenging goal. Extensive studies on HIV-1 have revealed various strategies employed by the virus to escape host immune surveillance. Here, we investigated the human antibody gene repertoires of uninfected and HIV-1-infected individuals at genomic DNA (gDNA) and cDNA levels by deep sequencing followed by high-throughput sequence analysis to determine the frequencies of putative germline antibody genes of known HIV-1 monoclonal bnAbs (bnmAbs).Methods:Combinatorial gDNA and cDNA antibody libraries were constructed using the gDNAs and mRNAs isolated from uninfected and HIV-1-infected human peripheral blood mononuclear cells (PBMCs). All libraries were deep sequenced and sequences analysed using IMGT/HighV-QUEST software (http://imgt.org/HighV-QUEST/index.action). The frequencies of putative germline antibodies of known bnmAbs in the gDNA and cDNA libraries were determined.Results and conclusion:The human gDNA antibody libraries were more diverse in heavy and light chain V-gene lineage usage than the cDNA libraries, indicating that the human gDNA antibody gene repertoires may have more potential than the cDNA repertoires to develop HIV-1 bnAbs. The frequencies of the heavy and kappa and lambda light chain variable regions with identical V(D)J recombinations to known HIV-1 bnmAbs were extremely low in human antibody gene repertoires. However, we found relatively high frequencies of the heavy and kappa and lambda light chain variable regions that used the same V-genes and had the same CDR3 lengths as known HIV-1 bnmAbs regardless of (D)J-gene usage. B-cells bearing B-cell receptors of such heavy and kappa and lambda light chain variable regions may be stimulated to induce HIV-1 bnAbs. (C) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins

HIV-1 Antibodies from Infection and Vaccination: Insights for Guiding Vaccine Design

Antibody‐virus Co‐evolution in HIV Infection: Paths for HIV Vaccine Development

E108 Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design

Broadly neutralizing antibodies and vaccine design against HIV-1 infection

Ontogeny‐based immunogens for the induction of V2‐directed HIV broadly neutralizing antibodies

[Advances in the Immunogenic Design of HIV-1 Vaccine].

Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens

Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design

The Potential Of The Human Immune System To Develop Broadly Neutralizing Hiv-1 Antibodies: Implications For Vaccine Development

A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses

Broadly neutralizing antibodies against human immunodeficiency virus type 1(HIV-1) and rational design of HIV-1 vaccines

Antibody-based Candidate Therapeutics Against HIV-1: Implications for Virus Eradication and Vaccine Design

Identification and specificity of broadly neutralizing antibodies against HIV

A vaccine strategy for inducing broadly neutralizing antibodies against HIV

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction

B Cell Responses to HIV-1 Infection and Vaccination: Pathways to Preventing Infection

HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing Antibodies

Vaccination induces broadly neutralizing antibody precursors to HIV gp41

Targeted selection of HIV-specific antibody mutations by engineering B cell maturation

HIV Vaccine Development at a Crossroads: New B and T Cell Approaches